November 1, 2000 |
Edwards Lifesciences Corp.'s stock was hammered after the company said it is lowering its profit estimates for the fourth quarter and 2001 because of a weak euro and sluggish sales in several product lines. Shares of the Irvine company, which makes products that treat cardiovascular disease, plummeted more than 41%, the fifth biggest percentage loss in U.S. markets for the day. The stock closed at $13.44, down $9.50 a share, on the New York Stock Exchange.
April 22, 2000 |
Edwards Lifesciences Corp., the largest maker of replacement heart valves, said Friday it has halted use of its surgical patches for protecting dangerously weakened aortas after spotting small cracks in the patches. Routine X-rays of two patients in a trial of the Lifepath AAA Endovascular Graft System revealed the cracks. Neither patient had medical problems as a result of the damaged products.
July 19, 2000 |
Edwards Lifesciences Corp., the No. 1 maker of artificial heart valves, agreed on Tuesday to sell most of its unprofitable Bentley line to Germany's Jostra for about $30 million and said it plans to take charges against earnings related to the sale and severance costs for 60 employees at its Irvine headquarters and in Puerto Rico. Edwards, which was spun off by Baxter International Inc.
April 1, 2000 |
Shares of Edwards Lifesciences Corp., an Irvine developer of cardiovascular products, are scheduled to begin trading officially Monday amid a bullish earnings outlook. The new company, which is being shed by Baxter International Inc. in Deerfield, Ill., will compete against Boston Scientific Corp., Guidant Corp. and Medtronic Inc. in providing products to treat cardiovascular disorders, a market Edwards estimates at $100 billion a year.
June 13, 2000 |
Irvine-based Edwards Lifesciences Corp., which makes products to treat heart disease, said it received approval from the Food and Drug Administration to sell its Thrombex PMT System, which removes blood clots from grafted blood vessels. The stock closed at $18.63, up 13 cents a share, on the New York Stock Exchange.
June 22, 2000 |
Edwards Lifesciences Corp. in Irvine received Food and Drug Administration approval to begin selling its Vantex central venous catheter. Shares of the company, which develops products and services to treat late-stage cardiovascular disease, rose $1.19, or nearly 7%, to $19, on the New York Stock Exchange.
January 24, 2006 |
Edwards Lifesciences Corp. said it agreed to settle a patent dispute with Medtronic Inc. and Medtronic Vascular Inc. over grafts used to treat various aneurysms. Irvine-based Edwards said that in exchange for a payment of $37.5 million to Edwards and Australia-based Endogad Research Party Ltd., Medtronic had been granted nonexclusive licenses to the patents involved in the litigation and related patents.